The incidence of secondary malignancies rises after HCT, with the most common occurrences in the oral cavity, skin, breast, and thyroid. A consensus report developed jointly by CIBMTR (Center for International Blood and Marrow Transplant Research) and EBMT (European Society for Blood and Marrow Transplantation) has established guidelines to help clinicians implement annual screening and preventive care for secondary cancers among HCT recipients. Post-HCT screening recommendations are organ and site-specific, based on general guidelines from the American Cancer Society and National Comprehensive Cancer Network. Well-documented risk factors for many types of secondary cancers, including myeloablative total body irradiation, young age at HCT, chronic GVHD, and prolonged immunosuppressive treatment beyond 24 months should be considered when applying these recommendations to individual care plans.
Inamoto Y, et al. Bone Marrow Transplant
Patient-level summary of this study